Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52819
Conference/Presentation Title: Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni Syndrome.
Authors: Zaheed M.;Napier C.E.;Cops E.J.;Ferris N.;Moodie K.;Milner B.;Moses D.;Poplawski N.;Dow E.G.;Harris M. ;Tucker K.;Trainer A.;James P.;Thomas D.M.;Ballinger M.L.
Monash Health Department(s): Oncology
Institution: (Zaheed, Napier, Cops, Ferris, Moodie, Milner, Moses, Poplawski, Dow, Harris, Tucker, Trainer, James, Thomas, Ballinger) Garvan Institute of Medical Research, Darlinghurst, Australia; Garvan Institute of Medical Research, Sydney, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Monash Health, Clayton, Australia; St Vincents Hospital, Darlinghurst, Australia; Prince of Wales Hospital, Randwick, Australia; Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, Australia; Royal Adelaide Hospital, Adelaide, Australia; Monash Health, Bentleigh East, VIC, Australia; Peter MacCallum, Melbourne, Australia; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia
Presentation/Conference Date: 16-Nov-2024
Copyright year: 2023
Publication information: Journal of Clinical Oncology. Conference: 2023 American Society of Clinical Oncology Annual Meeting, ASCO. Chicago, IL United States. 41(16 Supplement) (pp 10578), 2023. Date of Publication: June 2023.
Journal: Journal of Clinical Oncology
Abstract: Background: Li Fraumeni Syndrome (LFS) is a high penetrance multi-organ cancer predisposition syndrome, associated with a significant lifetime risk of developing cancer. The Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) is investigating the utility of annual surveillance, with inclusion of whole-body magnetic resonance imaging (WBMRI), for hereditary cancer syndromes without well-established risk management strategies. Here we report the long-term clinical and psychosocial outcome of surveillance in participants with LFS. Method(s): Multimodality surveillance in this multi-centre, prospective, longitudinal, observational study for adult participants with LFS included annual clinic review and examination, WBMRI, breast MRI (MRIB), full blood count, prostate specific antigen; 2-5 yearly gastro-intestinal endoscopy and faecal occult blood test in intervening years. Quantitative psychometric evaluations were requested at regular intervals each year using Hospital Anxiety and Depression Scale (HADS), the Impact of Events scale anchored to cancer (IES-C), and the Impact of Events scale MRI (IES-MRI). Result(s): From July 2013 to December 2021, 132 (67% female) participants were enrolled at a median age of 36 (range 18-69 )years. There were 116 prior diagnoses of neoplasms among 68 (52%) participants, including 27 (20%) with multiple primaries. At a median follow up of 4 years, 46 new primary malignancies were diagnosed in 30 (23%) individuals, with median age at diagnosis of 43 (range 24-71 years). Four (3%) individuals developed recurrence of a prior malignancy. The malignancies were detected as a result of WBMRI (27), MRIB (7), gastroscopy (1), colonoscopy (1) and clinical review and examination (17). The most frequent new primaries were leiomyosarcoma and breast cancer (Table). Overall, 22 (17%) are not currently participating due to cancer related death (10), active cancer (6) or other life events (6). At 4 years after enrollment, 94, 80 and 50 participants completed at least one HADS (463 unique observations), IES-C (362 unique observations), and IES-MRI (268 unique observations) questionnaire, respectively. Controlling for demographic and cancer history variables, there was no evidence of changes in overall anxiety or depression (p=0.2), nor in degrees of distress associated with cancer (p=0.06) or WBMRI (p=0.6) over time. Conclusion(s): In LFS, annual surveillance with WBMRI is feasible and well tolerated, with no difference in distress experienced in the longer term. Over 80% of participants continue to engage with surveillance. The majority of cancer-affected individuals were able to resume surveillance after management of early disease.
Conference Name: 2023 American Society of Clinical Oncology Annual Meeting, ASCO
Conference Start Date: 2023-06-02
Conference End Date: 2024-11-19
Conference Location: Chicago, IL, United States
DOI: http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1200/jco.2023.41.16_suppl.10578
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/52819
Type: Conference Abstract
Subjects: breast cancer
breast magnetic resonance imaging
endoscopy
gastroscopy
Li-Fraumeni syndrome
nuclear magnetic resonance imaging
whole body MRI
Type of Clinical Study or Trial: Observational study (cohort, case-control, cross sectional, or survey)
Appears in Collections:Conferences

Show full item record

Page view(s)

30
checked on Mar 13, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.